Prognostic Methylation Markers for Survival in Cytogenetically Normal AML Patients Treated on SWOG Trials

被引：0
|
作者：
Qu, Xiaoyu [1 ,2 ]
Othus, Megan [1 ,3 ]
Davison, Jerry [1 ]
Yan, Liying [4 ]
Estey, Elihu H. [2 ,5 ,6 ]
Radich, Jerry [1 ,2 ,3 ,7 ]
Erba, Harry P. [3 ,8 ]
Appelbaum, Frederick R. [1 ,2 ,3 ,7 ]
Fang, Min [1 ,2 ,3 ,7 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] SWOG Leukemia Comm, Portland, OR USA
[4] EpigenDx Inc, Boston, MA USA
[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[6] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[7] Univ Washington, Seattle, WA 98195 USA
[8] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] PROGNOSTIC SIGNIFICANCE OF MOLECULAR MARKERS IN NORMAL KARYOTYPE -AML: A SINGLE CENTER EXPERIENCE
    Spinelli, O.
    Tosi, M.
    Guerini, V
    Zanghi, P.
    Franchi, M.
    Taboni, I
    Magri, M.
    Zanotti, M.
    Intermesoli, T.
    Oldani, E.
    Bassan, R.
    Rambaldi, A.
    HAEMATOLOGICA, 2008, 93 : S52 - S52
  • [32] Prognostic impact of BAALC expression in the context of other molecular markers in cytogenetically normal acute myeloid leukemia
    Dohner, Konstanze
    Corbacioglu, Andrea
    Eiwen, Karina
    Ewert, Judith
    Frohling, Stefan
    Bullinger, Lars
    Krauter, Juergen
    Schlegelberger, Brigitte
    Ganser, Arnold
    Dohner, Hartmut
    Schlenk, Richard F.
    BLOOD, 2007, 110 (11) : 1021A - 1021A
  • [33] Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks
    Deneberg, Stefan
    Guardiola, Philippe
    Lennartsson, Andreas
    Qu, Ying
    Gaidzik, Verena
    Blanchet, Odile
    Karimi, Mohsen
    Bengtzen, Sofia
    Nahi, Hareth
    Uggla, Bertil
    Tidefelt, Ulf
    Hoglund, Martin
    Paul, Christer
    Ekwall, Karl
    Doehner, Konstanze
    Lehmann, Soren
    BLOOD, 2011, 118 (20) : 5573 - 5582
  • [34] The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia
    He, Xue
    Zhang, Weilong
    Fu, Wei
    Liu, Xiaoni
    Yang, Ping
    Wang, Jing
    Zhu, Mingxia
    Li, Shaoxiang
    Zhang, Wei
    Zhang, Xiuru
    Dong, Gehong
    Yan, Changjian
    Zhao, Yali
    Zeng, Zhiping
    Jing, Hongmei
    CANCER BIOMARKERS, 2023, 36 (02) : 103 - 116
  • [35] Prognostic Markers in Glioblastoma Patients Treated with Temozolomide
    McMillan, Nadia
    Zhang, Shuodan
    McGuinness, Matthew
    Trudeau, Stephen
    Uhlmann, Erik
    NEUROLOGY, 2023, 100 (17)
  • [36] Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
    Taskesen, Erdogan
    Bullinger, Lars
    Corbacioglu, Andrea
    Sanders, Mathijs A.
    Erpelinck, Claudia A. J.
    Wouters, Bas J.
    van der Poel-van de Luytgaarde, Sonja C.
    Damm, Frederik
    Krauter, Juergen
    Ganser, Arnold
    Schlenk, Richard F.
    Lowenberg, Bob
    Delwel, Ruud
    Doehner, Hartmut
    Valk, Peter J. M.
    Doehner, Konstanze
    BLOOD, 2011, 117 (08) : 2469 - 2475
  • [37] Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience
    Yamamoto, N
    Tamura, T
    Yamamoto, N
    Fukuoka, M
    Saijo, N
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (04) : 737 - 741
  • [38] Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2
    vanBezooijen, RL
    Goey, H
    Stoter, G
    Hermans, J
    Fleuren, GJ
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1996, 43 (05) : 293 - 298
  • [39] Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2
    Van Bezooijen R.L.
    Goey H.
    Stoter G.
    Hermans J.
    Fleuren G.J.
    Cancer Immunology, Immunotherapy, 1997, 43 (5) : 293 - 298
  • [40] CDKN2B Methylation Correlates with Survival in AML Patients
    Dolatabadi, Esmat Kamali
    Dehaghi, Mohammadreza Ostadali
    Amirizadeh, Naser
    Parivar, Kazem
    Mahdian, Reza
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2017, 16 (04): : 1600 - 1611
12345